Cargando…
Is blood pressure reduction a valid surrogate endpoint for stroke prevention? an analysis incorporating a systematic review of randomised controlled trials, a by-trial weighted errors-in-variables regression, the surrogate threshold effect (STE) and the biomarker-surrogacy (BioSurrogate) evaluation schema (BSES)
BACKGROUND: Blood pressure is considered to be a leading example of a valid surrogate endpoint. The aims of this study were to (i) formally evaluate systolic and diastolic blood pressure reduction as a surrogate endpoint for stroke prevention and (ii) determine what blood pressure reduction would pr...
Autores principales: | Lassere, Marissa N, Johnson, Kent R, Schiff, Michal, Rees, David |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3388460/ https://www.ncbi.nlm.nih.gov/pubmed/22409774 http://dx.doi.org/10.1186/1471-2288-12-27 |
Ejemplares similares
-
Surrogate endpoints.
por: Ellenberg, S. S.
Publicado: (1993) -
Need for better reporting of trials with surrogate endpoints: SPIRIT|CONSORT-SURROGATE extensions
por: Ciani, Oriana, et al.
Publicado: (2022) -
The evaluation of surrogate endpoints
por: Burzykowski, Tomasz, et al.
Publicado: (2005) -
Surrogate Endpoints in Medicine
por: Srivastava, Sudhir, et al.
Publicado: (2002) -
Protocol for the development of SPIRIT and CONSORT extensions for randomised controlled trials with surrogate primary endpoints: SPIRIT-SURROGATE and CONSORT-SURROGATE
por: Manyara, Anthony Muchai, et al.
Publicado: (2022)